Skip to main content

Month: July 2024

DSV, 1119 – SHARE BUYBACK IN DSV A/S

Company Announcement No. 1119 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.Trading day Number of shares bought back   Average transaction price   Amount DKK             Accumulated trading...

Continue reading

Form 8.5 (EPT/NON-RI) – Alpha Financial Markets Consulting Plc

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Alpha Financial Markets Consulting plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to Alpha Financial Markets Consulting plc(d)        Date dealing undertaken: 01st July 2024(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If...

Continue reading

Virtune AB (Publ) is launching Virtune XRP ETP on Nasdaq Stockholm

Stockholm, July 2, 2024 – Virtune, a Swedish regulated digital asset manager, is announcing the launch of Virtune XRP ETP on Nasdaq Stockholm, the largest stock exchange in the Nordic region.  About Virtune XRP ETPVirtune XRP ETP provides exposure to XRP. Like all of Virtune’s exchange-traded products, Virtune XRP ETP is 100% physically backed and fully collateralized, is denominated in SEK for the Nordic audience and is available on Avanza and Nordnet. Key Information about Virtune XRP ETP:1:1 exposure to XRP 100% physically backed 1.49% annual management feeVirtune XRP ETPFull name: Virtune XRP ETP  Short name: Virtune XRP Ticker: VIRXRP Trading currency: SEK First day of trading: Tuesday 2nd of July 2024 ISIN: SE0021486156 Stock exchange: Nasdaq StockholmAbout XRPXRP is a crypto asset designed...

Continue reading

Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.

Ålesund, 02.07.24, Hofseth BioCare ASA (“HBC” or the “Company”), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate MA-022a to its majority-owned subsidiary HBC Immunology Inc. (“HBCI”). The patent underlying the project has been valued by KWC AS at $4.5m (based on relief-from royalty method) and HBC will therefore receive 956,813 common shares in HBCI for the transfer of the patent to HBCI.  HBC has booked approximately NOK 7.4m in costs relating to the patent as per June 1, 2024. Transfer of the patent will generate an approximately NOK 7.9m financial gain for HBC in Q2/2024 based on today’s exchange rate. Eosinophils are immune cells that become overactive in allergic and hypersensitivity conditions including allergic...

Continue reading

Preliminary revenue figures for the 2023/24 financial year

ANNOUNCEMENT NO. 270 2 July 2024 Preliminary revenue figures for the 2023/24 financial year In the fourth quarter of the 2023/24 financial year, ChemoMetec’s revenue was DKK 109.2 million, corresponding to a growth of 13.5% from the year-earlier period. The revenue for the 2023/24 financial year was DKK 407.4 million against DKK 442.3 million the previous year, corresponding to a decrease of 7.9%. The revenue in 2023/24 is thus in line with the latest disclosed guidance for the revenue of DKK 400-415 million, disclosed on 8 May 2024. In the fourth quarter of 2023/24, ChemoMetec sold XcytoMatic instruments for DKK 4.4 million, an increase of 69% compared to the third quarter of the financial year. Revenue by product groupDKKm Q4 2023/24 Q4 2022/23 Q3 2023/24 2023/24 2022/23Instruments 32.2 32.0 23.1 117.1 179.0Consumables 50.4 41.8 52.6 192.5 174.4Services 25.4 21.4 22.1 93.5 83.0Other 1.2 1.0 1.1 4.3 5.9Total...

Continue reading

VINCI finalises acquisition of MBO Groupe

 Nanterre, 2 July 2024 VINCI finalises acquisition of MBO GroupeMBO Groupe is a prominent French player in industrial services in general, and particularly active in the nuclear sector Its 500 employees generated €85 million in revenue in 2023 The acquisition strengthens Nuvia’s range of expertiseNuvia, VINCI Construction’s subsidiary specialised in projects and services in the nuclear sector, has finalised the acquisition of MBO Groupe, a prominent player in thermal insulation, scaffolding and confinement in France. The company is active in a variety of industrial areas, including the nuclear sector where it provides maintenance services and works on large complex new-build projects. MBO Groupe’s 500 employees at some 15 bases generated around €85 million in revenue in 2023. The acquisition strengthens Nuvia’s range of industrial...

Continue reading

Notification of voluntary takeover offer regarding the shares of AS Tallink Grupp

Today, on 2 July 2024, a shareholder of AS Tallink Grupp, AKTSIASELTS INFORTAR (registry code: 10139414, “Offeror”), has notified of making a voluntary takeover offer to acquire all shares of AS Tallink Grupp not yet belonging to the Offeror with a price of EUR 0.55 per share. Below we publish the Offeror’s notice regarding the voluntary takeover offer together with the prospect annexed to it. _________________________________________________________________________________ NOTICE OF VOLUNTARY TAKEOVER OFFER TO ACQUIRE SHARES OF AKTSIASELTS TALLINK GRUPPTakeover offer and OfferorAS Infortar (company registered in Estonia with registry code 10139414 and registered address Liivalaia 9, 10118, Tallinn, Estonia, “Offeror”) in accordance with the Securities Market Act (“SMA”) and other applicable legal acts hereby makes a voluntary takeover...

Continue reading

Notification of voluntary takeover offer regarding the shares of AS Tallink Grupp

Today, on 2 July 2024, a shareholder of AS Tallink Grupp, AKTSIASELTS INFORTAR (registry code: 10139414, “Offeror”), has notified of making a voluntary takeover offer to acquire all shares of AS Tallink Grupp not yet belonging to the Offeror with a price of EUR 0.55 per share. Below we publish the Offeror’s notice regarding the voluntary takeover offer together with the prospect annexed to it. _________________________________________________________________________________ NOTICE OF VOLUNTARY TAKEOVER OFFER TO ACQUIRE SHARES OF AKTSIASELTS TALLINK GRUPPTakeover offer and OfferorAS Infortar (company registered in Estonia with registry code 10139414 and registered address Liivalaia 9, 10118, Tallinn, Estonia, “Offeror”) in accordance with the Securities Market Act (“SMA”) and other applicable legal acts hereby makes a voluntary takeover...

Continue reading

Fingerprints™ and IN Groupe through SPS brand announce launch of its secure Component solution for contactless biometric cards

Fingerprint Cards AB (Fingerprints™) and IN Groupe through SPS brand, leader in contactless and dual interface cards, announce the launch of its secure Component solution for contactless biometric payment cards, supporting global card manufacturers to scale up production of next-generation payment cards. In line with consumer preferences for contactless, the global biometric payment card market is anticipated to rise at a considerable rate over the coming years. To support mass global adoption, Fingerprints and IN Groupe partnered in November 2023 with the aim to simplify the manufacturing process, allowing for increased production by improving reliability and reducing costs. Through SPS brand of IN Groupe, the next-generation cards are now ready for mass global rollout. The CEO of Fingerprints, Adam Philpott, comments: “Our continuing...

Continue reading

Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.

PRESS RELEASE – PRIVILEGED INFORMATION  The adapted supply and commercialization conditions to better achieve the development of the first oral formulation of arsenic trioxide for the treatment of cGvHD should provide the best chances for final market access. Mont-Saint-Guibert, Belgium, July 2, 2024, 7.00am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announce the signature of global licensing, supply and commercialization agreements with Phebra Pty Ltd. related to the adaptation of the License Agreement and the MDA signed earlier in May 2021, when Phebra became a minority shareholder in Medsenic SAS. The improved terms will make it more attractive for investors to participate in the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.